



# Our investment in metastatic breast cancer research

In 2019, the Canadian Cancer Society invested \$3.2 million in projects specifically focused on metastatic breast cancer (MBC). This represented around one-quarter of its total \$14.3 million breast cancer research investment last year. Through partnerships, CCS leveraged another \$597,373 for a total of \$3.8 million.

In the last 10 years, CCS and the former Canadian Breast Cancer Foundation have together invested more than \$54.4 million in MBC research, representing more than 25% of their total breast cancer research investment.

Current research topics include:

- The effect of diet and exercise in chemotherapy response in patients with MBC
- How breast cancer develops and spreads to different organs, and new ways to stop it
- Combining radiation with nanoparticles to treat and limit the spread of triple negative breast tumours while minimizing side effects

CCS is committed to supporting the best breast cancer research in Canada, including critical research on how breast cancer spreads and how we can prevent and treat metastatic breast cancer more effectively and improve quality of life for those living with the disease.

## **Metastatic Breast Cancer Dream Team**

In August 2019, CCS collaborated with the Canadian Institutes of Health Research (CIHR) and Stand Up to Cancer (SU2C) Canada to announce the SU2C Canada Metastatic Breast Cancer Dream Team.

The Dream Team will receive up to \$6 million in funding over 4 years to conduct a nationwide clinical trial to test a new way of treating metastatic breast cancer. The trial's goal is to stop cancer cells from becoming aggressive and spreading to other organs. The Team is led by Dr Nahum Sonenberg of McGill University and Dr Michael Pollak of Lady Davis Institute and brings together a team of top cancer researchers from Edmonton, Kingston, Montreal, Vancouver and Victoria.


Over the past year, the researchers have completed the necessary paperwork to launch the trial. As of July 2020, the trial is ready to start at the Jewish General Hospital in Montreal with sites at the Cross Cancer Institute (Edmonton) and BC



Cancer (Vancouver) expected to open soon. The trial is also registered on [clinicaltrials.gov](https://clinicaltrials.gov).

### Breakdown of CCS's research investments

In 2019, CCS invested \$40.66 million in innovative and impactful cancer research across Canada. Below is a breakdown our research investment by type of grant and program:



Other: Travel Awards, Career awards, Quality of Life grants, Knowledge to Action grants, Prevention grants, special partnership funded grants, directed funding

